A recent clinical trial indicates that the hallucinogen DMT (dimethyltryptamine) shows significant promise as an antidepressant. In the study, nearly half of participants who received DMT reported feeling better one week after a single dose, compared to only 6 percent in the control group. While symptom improvement diminished by 14 weeks, participants who received DMT still showed lasting benefits.
Treatment with DMT resulted in no serious side effects. Minor, short-lived effects included injection site pain and brief increases in heart rate and blood pressure.
Researchers are exploring whether the hallucinogenic and antidepressant effects of psychedelics are linked. This study suggests that for DMT, these effects may not be separable, as the antidepressant response was moderated by scores on measures of mystical experience and ego dissolution.
While larger trials and longer follow-up periods are needed, this initial research indicates DMT could be a valuable therapeutic option, particularly for individuals who do not respond to traditional antidepressants. The drug's ability to significantly impact clinical depression with even a brief period of altered consciousness, alongside simplified care, marks a promising development.